Jpmorgan Chase & CO Puma Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 48,352 shares of PBYI stock, worth $255,298. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,352
Previous 136,897
64.68%
Holding current value
$255,298
Previous $417,000
65.71%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PBYI
# of Institutions
125Shares Held
33.4MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$21.8 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$19.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$18.9 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$10.6 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$9.9 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $241M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...